Aimia Inc. (TSX:AIM)
2.780
-0.090 (-3.14%)
At close: Mar 18, 2026
Aimia Revenue
Aimia had revenue of 126.40M CAD in the quarter ending September 30, 2025, a decrease of -2.09%. This brings the company's revenue in the last twelve months to 512.10M, up 8.11% year-over-year. In the year 2024, Aimia had annual revenue of 500.80M with 71.98% growth.
Revenue (ttm)
512.10M
Revenue Growth
+8.11%
P/S Ratio
0.51
Revenue / Employee
27.92M
Employees
18
Market Cap
256.16M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 500.80M | 209.60M | 71.98% |
| Dec 31, 2023 | 291.20M | 289.70M | 19,313.33% |
| Dec 31, 2022 | 1.50M | -11.10M | -88.10% |
| Dec 31, 2021 | 12.60M | -1.70M | -11.89% |
| Dec 31, 2020 | 14.30M | -113.00M | -88.77% |
| Dec 31, 2019 | 127.30M | -39.80M | -23.82% |
| Dec 31, 2018 | 167.10M | -65.00M | -28.01% |
| Dec 31, 2017 | 232.10M | -1.53B | -86.81% |
| Dec 31, 2016 | 1.76B | -701.30M | -28.50% |
| Dec 31, 2015 | 2.46B | -8.20M | -0.33% |
| Dec 31, 2014 | 2.47B | 795.30M | 47.52% |
| Dec 31, 2013 | 1.67B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Neo Performance Materials | 687.29M |
| AirBoss of America | 551.76M |
| 5N Plus | 536.19M |
| EcoSynthetix | 28.52M |
| California Nanotechnologies | 4.24M |
| International Parkside Products | 2.43M |
| Graphene Manufacturing Group | 267.39K |
| HydroGraph Clean Power | 85.59K |
Aimia News
- 2 days ago - AIMIA DECLARES PREFERRED SHARE DIVIDENDS - Benzinga
- 13 days ago - Verdict parent company GlobalData moves to Main Market of LSE - Verdict
- 16 days ago - AIM Collaborates with Thermo Fisher for Phase 3 Trial of Ampligen in Pancreatic Cancer - GuruFocus
- 16 days ago - AIMIA PROVIDES UPDATE ON ITS SHARE BUYBACKS - Benzinga
- 23 days ago - AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca's Durvalumab in the Treatment of Metastatic Pancreatic Cancer - Benzinga
- 4 weeks ago - AIMIA ANNOUNCES DUAL LISTING ON JOHANNESBURG STOCK EXCHANGE - Benzinga
- 4 weeks ago - IHG revenues up, ITM Power upgrades outlook and Debenhams funding round - The Armchair Trader
- 5 weeks ago - Aimia Inc. (AIM:CA) M&A Call Transcript - Seeking Alpha